SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Datsons Labs shines on partnering with Clinton Foundation to supply Anti-Malarial Drugs

09 Mar 2015 Evaluate

Dr. Datasons Labs is currently trading at Rs 8.22, up by 0.75 points or 10.04% from its previous closing of Rs. 7.47 on the BSE.

The scrip opened at Rs. 7.40 and has touched a high and low of Rs. 8.45 and Rs. 7.24 respectively. So far 2438690 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 70.80 on 10-Mar-2014 and a 52 week low of Rs. 6.03 on 25-Feb-2015.

Last one week high and low of the scrip stood at Rs. 8.46 and Rs. 6.62 respectively. The current market cap of the company is Rs. 90.74 crore.

The Institutions and Non-Institutions held 38.87% and 61.13% respectively.

Indian Drug maker Dr. Datsons Labs has received the proposal to supply the Artemisinin-based combination therapies (ACTs) to the Clinton Health Access Initiative (CHAI), the healthcare project of the Clinton Foundation. Dr. Datsons Labs will be making a significant deal though there is a minimum pricing that the company will be working on.

The volume will be huge because it will be supplied to most of the African countries. In the UNITAID-CHAI Malaria Treatment Project 2015, other big players such as Cipla, Ipea & other Indian players are already on the approved list of The Clinton Health Access Initiative (CHAI) to supply the drugs.

Dr. Datsons Labs is a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities. It is R&D focused, has a multi product portfolio with state of the art manufacturing facilities, and is set to become a marketing conglomerate across the globe.

Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×